Osaka Group Proposes Transferring Pharmaceutical Process Approval Authority To Prefecture Government
This article was originally published in PharmAsia News
Executive Summary
Osaka Bio Headquarters issued a proposal Nov. 11 asking the state government to transfer its pharmaceutical manufacturing review and approval authority to the prefecture government. The group is composed of the Osaka prefecture government, the Osaka Chamber of Commerce and Hankyo Railway, and has established measures to promote Osaka as a biology and pharmaceutical center. To speed up the drug development and commercialization process, the group suggests the Osaka prefecture government should review and approve process changes such as adding production lines and conducting good manufacturing practice inspections. The proposal will be presented to the Cabinet office Nov. 13. (Click here for more - Japanese language
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.